| 1. |
Mitsuru Watanabe, NfL and other candidate biomarkers in MS & NMOSD, PACTRIMS 2023, 2023.11, Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease of the central nervous system. In clinical practice, disease activity is mainly assessed by clinical evaluation and neuroimaging. However, more sensitive biomarkers reflecting disease activity are needed to improve the prognosis. The levels of neurofilament light chain (NfL), one of three types of neuronal intermediate filament, elevate upon neuroaxonal damage not only in cerebrospinal fluid but also in blood. In MS, many studies showed that blood NfL can be a good biomarker representing disease activity, treatment response and prognosis. Therefore, blood NfL is expected to be used in daily clinical practice in the future to monitor disease activity and predict prognosis in each individual. Neuromyelitis optica spectrum disorder (NMOSD) is an autoimmune astrocytopathy mediated by anti-aquaporin 4 antibody that typically presents with severe and recurrent attacks in the optic nerve and spinal cord. Glial fibrillary acidic protein (GFAP), an intermediate filament of astrocytes, in blood is reported to be associated with disease activity and disability in NMOSD. This lecture provides updates on biofluid biomarkers including NfL and GFAP in MS and NMOSD and discuss whether they can be applied to clinical practice.. |
| 2. |
Mitsuru Watanabe, Katsuhisa Masaki, Eizo Tanaka, Takuya Matsushita, Noriko Isobe, Efficacy of Eculizumab in Acute Phase of Neuromyelitis Optica Spectrum Disorder: A Case Series Study, PACTRIMS 2023, 2023.11. |
| 3. |
Mitsuru Watanabe, Katsuhisa Masaki, Eizo Tanaka, Takuya Matsushita, Noriko Isobe, Case series of eculizumab treatment on NMOSD attacks, MS Milan2023, 2023.10. |
| 4. |
Mitsuru Watanabe, Noriko Isobe, Takuya Matsushita, Aleksandra Maceski, Yuri Nakamura, Katsuhisa Masaki, Jun-ichi Kira*, David Leppert*, Jens Kuhle*
*These authors contributed equally to the manuscript.
, Serum glial fibrillary acidic protein, but not S100B or neurofilament light chain predicts future relapses in neuromyelitis optica spectrum disorders, MSVirtual 2020 (8th Joint ACTRIMS-ECTRIMS Meeting), 2020.09. |
| 5. |
Mitsuru Watanabe, Yuri Nakamura, Noriko Isobe, Masami Tanaka, Ayako Sakoda, Fumie Hayashi, Takuya Matsushita, Jun-ichi Kira, Effect of HLA class II alleles on JCV infection in Japanese patients with multiple sclerosis, ECTRIMS 2019, 2019.09. |
| 6. |
Mitsuru Watanabe, Yuri Nakamura, Zuzanna Michalak, Fumie Hayashi, Christian Barro, David Leppert, Noriko Isobe, Takuya Matsushita, Ryo Yamasaki, Jens Kuhle, Jun-ichi Kira, Serum GFAP and neurofilament light as biomarkers of disease activity and disability in NMOSD and MS, 第60回日本神経学会学術大会, 2019.05. |
| 7. |
Mitsuru Watanabe, Yuri Nakamura, Zuzanna Michalak, Fumie Hayashi, Christian Barro, Noriko Isobe, Takuya Matsushita, Ryo Yamasaki, Jens Kuhle, Jun-ichi Kira, Serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) in neuromyelitis optica spectrum disorders, ECTRIMS 2018, 2018.10. |
| 8. |
Mitsuru Watanabe, Yuri Nakamura, Zuzanna Michalak, Fumie Hayashi, Christian Barro, Noriko Isobe, Takuya Matsushita, Ryo Yamasaki, Jens Kuhle, Jun-ichi Kira
, Serum glial fibrillary acidic protein (GFAP) and neurofilament light chain (NfL) as potential biomarkers for disease activity and disability in neuromyelitis optica spectrum disorders and multiple sclerosis
, 11th PACTRIMS Congress, 2018.11. |
